留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价

陶伊琳 黄幼明 林惠娥

陶伊琳, 黄幼明, 林惠娥. 选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价[J]. 药学实践与服务, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
引用本文: 陶伊琳, 黄幼明, 林惠娥. 选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价[J]. 药学实践与服务, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
TAO Yilin, HUANG Youming, LIN Huie. A systematic review on the correlation between selective dipeptidyl peptidase inhibitor vildagliptin and risk of arthralgia/osteoarthritis[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
Citation: TAO Yilin, HUANG Youming, LIN Huie. A systematic review on the correlation between selective dipeptidyl peptidase inhibitor vildagliptin and risk of arthralgia/osteoarthritis[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015

选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价

doi: 10.3969/j.issn.1006-0111.2016.06.015

A systematic review on the correlation between selective dipeptidyl peptidase inhibitor vildagliptin and risk of arthralgia/osteoarthritis

  • 摘要: 目的 系统评价选择性二肽基肽酶(DPP)-4抑制剂维格列汀与关节痛/骨关节炎发病风险的相关性。 方法 利用计算机检索PubMed(1978.01-2016.02)、Cochrane Library(2015年第4期)、EMbase(1974.01-2016.02)、CBM(1978.01-2016.02)、CNKI(1978.01-2016.02)、VIP(1989.01-2016.02)的所有相关文献。根据Cochrane系统评价方法筛选维格列汀治疗2型糖尿病发生关节痛/骨关节炎的所有中、英文随机对照试验(RCT),对纳入文献进行数据提取和质量评价后,采用RevMan 5.3软件进行荟萃(Meta)分析。 结果 共纳入10篇文献。Meta分析结果显示:使用维格列汀与使用其他降糖药或安慰剂相比,发生关节痛/骨关节炎的风险更高,差异有统计学意义[RR=1.24,95% CI(1.08,1.44),P=0.003]。进一步分析表明,各种剂量维格列汀组关节痛/骨关节炎的发病风险高于安慰剂组,差异有统计学意义[RR=1.35,95% CI(1.02,1.78),P=0.04]。尤其50 mg,1次/d维格列汀致关节痛/骨关节炎的发病风险显著高于安慰剂组,差异有统计学意义[RR=3.04,95% CI(1.44,6.44),P=0.004]。与其他降糖药比较,发现维格列汀组关节痛/骨关节炎的发病风险更高,差异有统计学意义[RR=1.19,95% CI(1.01,1.41),P=0.04]。 结论 维格列汀可增加关节痛/骨关节炎的发病风险。尤其50 mg,1次/d维格列汀可使关节痛/骨关节炎的发病风险增加2倍。但其远期的安全性还需进行更多大样本、高质量、长期随访的RCT加以验证。
  • [1] Gu D, Reynolds K,Duan X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population:international collaborative study of cardiovascular disease in Asia (InterASIA)[J]. Diabetologia, 2003, 46(9):1190-1198.
    [2] Yang W, Liu JM, Weng JP, et al. Prevalence of diabetes among men and women in China[J].N Engl J Med, 2010,362(12):1090-1101.
    [3] Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibitors:a promising new therapeutic approach for the management of type 2 diabetes[J]. Int J Biochem Cell Biol, 2006, 38(5-6):831-844.
    [4] Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes[J]. J Clin Endocrinol Metab, 2004, 89(5):2078-2084.
    [5] Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2005,90(8):4888-4894.
    [6] American Diabetes Association. Standards of medical care in diabetes——2015:summary of revisions[J]. Diabetes Care,2015,38(Suppl):S4.
    [7] Hirose T, Suzuki M,Tsumiyama I. Efficacy and safety of vildagliptin as an add-on to insulin with or without metformin in Japanese patients with type 2 diabetes mellitus:a 12-week, double-blind, randomized study[J]. Diabetes Ther,2015,6(4):559-571.
    [8] FDA safety alert. FDA Drug Safety Communication:FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain[EB/OL].[2015-08-28] (2016-02-29).http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm.
    [9] Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0[EB/OL].[2011-03-01] (2016-02-29).http://handbook.cochrane.org/
    [10] CLAF237A2329. A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF23750 mg bid to 50 mg qd in patients with type 2 diabetes with HbAlc 9-11%[EB/OL].[2007-03-16] (2016-02-29). http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2297.
    [11] CLAF237B2224. A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes[EB/OL].[2013-09-11] (2016-02-29).http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=9923.
    [12] Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin[J]. World J Diabetes,2010,1(1):19-26.
    [13] Garber AJ, Schweizer A,Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetesfailing thiazolidinedione monotherapy:a randomized, placebo-controlled study[J]. Diabetes Obes Metab, 2007,9(2):166-174.
    [14] Macauley M, Hollingsworth KG, Smith FE, et al. Effect of vildagliptin on hepatic steatosis[J]. J Clin Endocrinol Metab, 2015,100(4):1578-1585.
    [15] Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus[J].Diabetes Obes Metab, 2009,11(6):571-578.
    [16] Strain WD, Lukashevich V,Kothny W, et al. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL):a 24 week, randomised, double-blind, placebo-controlled study[J]. Lancet,2013,382(9890):409-416.
    [17] Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia[J]. Diabetes Obes Metab,2008,10(11):1114-1124.
    [18] Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia[J]. Diabetes Obes Metab, 2008,10(8):675-682.
    [19] Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain:results from a 2-year study[J]. Diabetes Obes Metab,2010,12(9):780-789.
    [20] Ospelt C, Mertens JC, Jüngel A, et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts[J]. Arthritis Rheum, 2010,62(5):1224-1235.
    [21] Yan S, Marguet D, Dobers J, et al. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen[J]. Eur J Immunol,2003,33(6):1519-1527.
    [22] K nig A, Krenn V, Toksoy A, et al. Mig,GRO alpha and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis[J]. Virchows Arch,2000,436(5):449-458.
    [23] Loetscher P, Moser B. Homing chemokines in rheumatoid arthritis[J]. Arthritis Res,2002,4(4):233-236.
    [24] Sedo A, Duke-Cohan JS, Balaziova E, et al. Dipeptidyl peptidase IV activity and/or structure homologs:contributing factors in the pathogenesis of rheumatoid arthritis[J]. Arthritis Res Ther,2005,7:253-269.
    [25] Busso N, Wagtmann N, Herling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis[J]. Am J Pathol,2005,166(2):433-442.
  • [1] 孙斌, 王子婧, 曹阳, 孟蕊, 杨岚, 朱金宝.  非甾体抗炎药治疗我国中老年骨关节炎疗效和安全性的网状Meta分析 . 药学实践与服务, 2021, 39(3): 259-266. doi: 10.12206/j.issn.1006-0111.202101022
    [2] 葛佳佳, 张莹莹.  β-内酰胺类联合大环内酯类药物治疗儿童社区获得性肺炎的有效性与安全性的Meta分析 . 药学实践与服务, 2021, 39(3): 274-279. doi: 10.12206/j.issn.1006-0111.202007077
    [3] 岑菁, 吕珊, 唐敏.  头孢他啶/阿维巴坦治疗碳青霉烯类耐药肠杆菌感染疗效和安全性的Meta分析 . 药学实践与服务, 2021, 39(4): 373-378. doi: 10.12206/j.issn.1006-0111.202007011
    [4] 廖小兰, 汪滢, 黄爱文, 郭秀强, 赖彦岚, 宋洪涛.  安罗替尼在治疗癌症患者中高血压的发生率和发生风险:一项系统评价和Meta分析 . 药学实践与服务, 2020, 38(6): 552-557. doi: 10.12206/j.issn.1006-0111.202008069
    [5] 金飞虹, 陈婕, 杨文超.  银杏二萜内酯葡胺注射液治疗脑梗死的疗效及安全性的Meta分析 . 药学实践与服务, 2019, 37(1): 80-85. doi: 10.3969/j.issn.1006-0111.2019.01.019
    [6] 林莉莉, 姚囡囡, 吴珏, 刘志宏, 宋洪涛.  糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析 . 药学实践与服务, 2019, 37(5): 473-480. doi: 10.3969/j.issn.1006-0111.2019.05.018
    [7] 袁颖超, 廖秋菊.  炎性细胞因子与膝骨关节炎诊断及治疗的最新研究进展 . 药学实践与服务, 2018, 36(1): 9-12. doi: 10.3969/j.issn.1006-0111.2018.01.002
    [8] 熊娟, 鹿辉, 王荣, 贾正平.  超重可能是急性高山病的危险因素:一项Meta分析 . 药学实践与服务, 2018, 36(5): 433-437. doi: 10.3969/j.issn.1006-0111.2018.05.011
    [9] 郑丽丽, 轩辕欢, 姜倩, 范芳芳, 姚莉, 赵生俊.  比较万古霉素持续输注与间断输注引起肾毒性的荟萃分析 . 药学实践与服务, 2018, 36(2): 136-139,146. doi: 10.3969/j.issn.1006-0111.2018.02.009
    [10] 白向荣, 程红勤, 张雁, 金颖.  两性霉素B膀胱冲洗治疗真菌尿的荟萃分析 . 药学实践与服务, 2018, 36(4): 379-384. doi: 10.3969/j.issn.1006-0111.2018.04.021
    [11] 应茵, 陆绪亮, 董威夷, 宋洪涛.  10 mg多廿烷醇与等剂量阿托伐他汀在血脂异常患者中调脂疗效比较的荟萃分析 . 药学实践与服务, 2017, 35(3): 282-288. doi: 10.3969/j.issn.1006-0111.2017.03.022
    [12] 刘留, 费素娟.  双歧杆菌三联活菌胶囊辅助根除幽门螺杆菌感染临床疗效的荟萃分析 . 药学实践与服务, 2016, 34(4): 380-384. doi: 10.3969/j.issn.1006-0111.2016.04.025
    [13] 万素馨, 黄道秋, 余蕾, 向毅, 方伟.  左氧氟沙星治疗耐多药肺结核疗效的系统评价/荟萃分析的质量评价 . 药学实践与服务, 2016, 34(6): 546-551. doi: 10.3969/j.issn.1006-0111.2016.06.016
    [14] 鲍思蔚, 张誉艺, 胡燕鸣, 翟晓波, 何志高.  氨曲南与头孢他啶治疗下呼吸道感染的荟萃分析 . 药学实践与服务, 2016, 34(1): 83-85,89. doi: 10.3969/j.issn.1006-0111.2016.01.022
    [15] 田怀平, 高蕙敏, 张金莲, 唐跃年.  拉莫三嗪治疗儿童及青少年失神性癫痫的系统评价 . 药学实践与服务, 2015, 33(3): 263-268. doi: 10.3969/j.issn.1006-0111.2015.03.020
    [16] 林秀丽, 石鹤坤, 陈尚瑜, 陈锦珊.  复方甘草酸苷片治疗慢性湿疹的荟萃分析 . 药学实践与服务, 2015, 33(4): 380-382,384. doi: 10.3969/j.issn.1006-0111.2015.04.024
    [17] 樊蓉, 任天舒, 赵庆春, 史国兵.  西药常规治疗联用通心络胶囊治疗冠心病心绞痛疗效的荟萃分析 . 药学实践与服务, 2015, 33(1): 83-87. doi: 10.3969/j.issn.1006-0111.2015.01.024
    [18] 路明珠, 陆文铨, 伊佳, 蔡国君.  不同分子量构成的玻璃酸钠对骨关节炎治疗作用的实验研究 . 药学实践与服务, 2010, 28(1): 19-22.
    [19] 张丽娜, 凌沛学, 张天民.  关节腔注射低分子肝素治疗兔膝骨关节炎的研究 . 药学实践与服务, 2008, (2): 110-114.
    [20] 刘树琴, 徐建华, 孙龙云, 孙桂华.  双氯芬酸钠凝胶治疗骨关节炎的疗效与安全性 . 药学实践与服务, 1997, (1): 3-5.
  • 加载中
计量
  • 文章访问数:  2845
  • HTML全文浏览量:  229
  • PDF下载量:  303
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-03-19
  • 修回日期:  2016-06-16

选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价

doi: 10.3969/j.issn.1006-0111.2016.06.015

摘要: 目的 系统评价选择性二肽基肽酶(DPP)-4抑制剂维格列汀与关节痛/骨关节炎发病风险的相关性。 方法 利用计算机检索PubMed(1978.01-2016.02)、Cochrane Library(2015年第4期)、EMbase(1974.01-2016.02)、CBM(1978.01-2016.02)、CNKI(1978.01-2016.02)、VIP(1989.01-2016.02)的所有相关文献。根据Cochrane系统评价方法筛选维格列汀治疗2型糖尿病发生关节痛/骨关节炎的所有中、英文随机对照试验(RCT),对纳入文献进行数据提取和质量评价后,采用RevMan 5.3软件进行荟萃(Meta)分析。 结果 共纳入10篇文献。Meta分析结果显示:使用维格列汀与使用其他降糖药或安慰剂相比,发生关节痛/骨关节炎的风险更高,差异有统计学意义[RR=1.24,95% CI(1.08,1.44),P=0.003]。进一步分析表明,各种剂量维格列汀组关节痛/骨关节炎的发病风险高于安慰剂组,差异有统计学意义[RR=1.35,95% CI(1.02,1.78),P=0.04]。尤其50 mg,1次/d维格列汀致关节痛/骨关节炎的发病风险显著高于安慰剂组,差异有统计学意义[RR=3.04,95% CI(1.44,6.44),P=0.004]。与其他降糖药比较,发现维格列汀组关节痛/骨关节炎的发病风险更高,差异有统计学意义[RR=1.19,95% CI(1.01,1.41),P=0.04]。 结论 维格列汀可增加关节痛/骨关节炎的发病风险。尤其50 mg,1次/d维格列汀可使关节痛/骨关节炎的发病风险增加2倍。但其远期的安全性还需进行更多大样本、高质量、长期随访的RCT加以验证。

English Abstract

陶伊琳, 黄幼明, 林惠娥. 选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价[J]. 药学实践与服务, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
引用本文: 陶伊琳, 黄幼明, 林惠娥. 选择性二肽基肽酶抑制剂维格列汀与关节痛/骨关节炎发病风险相关性的系统评价[J]. 药学实践与服务, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
TAO Yilin, HUANG Youming, LIN Huie. A systematic review on the correlation between selective dipeptidyl peptidase inhibitor vildagliptin and risk of arthralgia/osteoarthritis[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
Citation: TAO Yilin, HUANG Youming, LIN Huie. A systematic review on the correlation between selective dipeptidyl peptidase inhibitor vildagliptin and risk of arthralgia/osteoarthritis[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(6): 540-545. doi: 10.3969/j.issn.1006-0111.2016.06.015
参考文献 (25)

目录

    /

    返回文章
    返回